ULRICH BROECKEL, MD - FOUNDER & CHIEF EXECUTIVE OFFICER
Ulrich Broeckel, MD, is a leading clinician scientist with over 20 years of experience in genetics and genomics and more than 10 years of experience in clinical diagnostics. He is an expert in translational pharmacogenomic research, and is a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the NIH initiatives on clinical pharmacogenomics. Dr. Broeckel serves as Professor of Pediatrics, Section Chief of Genomic Pediatrics, and Director of the Individualized Medicine Institute at the Medical College of Wisconsin.
Gunter Scharer, MD - Chief Medical Officer
Gunter Scharer, MD, is a board-certified medical geneticist with over 15 years of clinical and laboratory experience. He is board certified in Clinical Genetics, Clinical Molecular Genetics, and Medical Biochemical Genetics, and licensed to practice in several states (CA, CO, MN, WI). Prior to joining RPRD Diagnostics, from 2015-2017, Dr. Scharer was the director of the Department of Medical Genetics and Genomics at Children's Minnesota and Adjunct Associate Professor in Pediatrics at the Medical College of Wisconsin.
Rachel Lorier - Director, Laboratory Operations
Rachel Lorier has over 10 years of experience developing the infrastructure and managing the operation of two clinical laboratories involved in cytogenetic and pharmacogenetic testing. At RPRD Diagnostics Rachel manages laboratory operations and oversees client relations. Ms. Lorier brings her many years of experience in research and clinical testing to provide clients with exceptional service.
Andrea Matter - Director, Regulatory Affairs
Andrea Matter has over 10 years of experience in clinical diagnostics, as well as FDA compliance. She has written extensive GMP documentation for NADA submission, as well as developed the regulatory infrastructure for two clinical laboratories under CAP/CLIA regulation. In her role at RPRD Diagonstics, Ms. Matter provides research and writes documentation to ensure clinical standards and safety regulations are consistently met.
Amy Turner - Director, Test Development
Amy Turner has over 10 years of experience in complex molecular test development, and over five years of experience supervising a clinical laboratory. She has developed a wide range of experimental methodologies, from detection of complex genetic variation, to exosomal biomarker screening. During Ms. Turner’s years in clinical research she has developed and validated multiple pharmacogenetic tests and will serve as the laboratory supervisor for pharmacogenetic test development and implementation.